StockNews.com began coverage on shares of Evoke Pharma (NASDAQ:EVOK – Free Report) in a report released on Tuesday. The brokerage issued a sell rating on the specialty pharmaceutical company’s stock.
Evoke Pharma Stock Performance
Shares of NASDAQ:EVOK opened at $4.51 on Tuesday. The stock’s 50-day simple moving average is $5.07 and its two-hundred day simple moving average is $5.92. The stock has a market capitalization of $38.77 million, a price-to-earnings ratio of -2.46 and a beta of 0.38. Evoke Pharma has a 52-week low of $3.54 and a 52-week high of $18.60.
Evoke Pharma (NASDAQ:EVOK – Get Free Report) last posted its quarterly earnings data on Tuesday, August 13th. The specialty pharmaceutical company reported ($0.93) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.21). Evoke Pharma had a negative return on equity of 964.25% and a negative net margin of 86.74%. The business had revenue of $2.55 million during the quarter.
Evoke Pharma Company Profile
Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.
Featured Stories
- Five stocks we like better than Evoke Pharma
- How to invest in marijuana stocks in 7 steps
- Analysts Predict 85% Upside for Wave Life Sciences After Rate Cut
- What is a Dividend King?
- FedEx Stock Dips: Another Reason to Fear Recession Is Near
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- The Half-Penny Revolution: Will SEC’s Reform Benefit Investors?
Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
